FDA Resurrects Park Doctrine in Enforcement of Pharmaceutical GMPs
This article was originally published in The Gold Sheet
Executive Summary
FDA is following through on earlier threats to dust off the long-dormant Park doctrine for holding chief executive officers of pharmaceutical companies personally accountable for manufacturing problems.